Real-world esketamine treatment for treatment-resistant depression: an analysis of comorbid post-traumatic stress disorder, comorbid anxiety disorder and line of therapy subgroups

Abstract

This paper describes subgroup analyses of a recent real-world study examining the impact of esketamine nasal spray combined with a newly initiated oral antidepressant (OAD) on quality-of-life and depression severity in participants with treatment-resistant depression (TRD). Patients with TRD, defined as major depressive disorder in adults who have not responded adequately to ≥2 different OADs of adequate dose and duration to treat the current depressive episode, were recruited from the esketamine early access program in Australia and New Zealand. Subgroups were defined by prior antidepressant medications received in the current depressive episode (2, 3–5, or ≥6) and post-traumatic stress dis..